Why Not Offer Your Tamoxifen Patients A Therapeutic Choice?
Patients may benefit from SOLTAMOX if they find it easier to take liquid medications or if they have difficulty swallowing tablets
Results of CAPTURE (Compliance and Preference for Tamoxifen Registry),1 an IRB-approved survey of 626 female breast cancer patients taking tamoxifen tablets, indicated that over 20% of patients were willing to try an oral liquid form of tamoxifen when presented with a choice.
Soltamox is bioequivalent to tamoxifen tablets
Same indications, side effects, and safety profile as tamoxifen tablets
- For treatment of adult patients with estrogen receptor-positive metastatic breast cancer
- For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer
- To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS)
- To reduce the incidence of breast cancer in adult women at high risk
1- Glück S, Sharma J, Belafsky PC, et al. CAPTURE (Compliance and Preference for Tamoxifen Registry) Patient Survey Reveals Potential Strategies to Improve Long-Term Adherence to TAM Based on Choice: Results of a Large Internet-Based Survey. J Natl Compr Canc Netn. 2014;12(4):455-456.9.
WARNING: UTERINE MALIGNANCIES and THROMBOEMBOLIC EVENTS
See full prescribing information for complete boxed warning.
- Serious, life-threatening, and fatal events from use of tamoxifen include uterine malignancies, stroke, and pulmonary embolism. (5.1, 5.2)
- Discuss risks and benefits of tamoxifen with women at high risk for breast cancer and women with ductal carcinoma in situ (DCIS) when considering tamoxifen use to reduce the risk of developing breast cancer. (5.1, 5.2)
- For most patients already diagnosed with breast cancer, the benefits of tamoxifen outweigh its risks. (5.1, 5.2)
SOLTAMOX® Important Safety Information
- Tamoxifen citrate is contraindicated in patients who require concomitant warfarin therapy, or a
history of deep vein thrombosis or pulmonary embolus, and in patients with known hypersensitivity
to the drug or any of its ingredients.
- Uterine malignancies: Promptly evaluate abnormal vaginal bleeding in a woman with current or
past tamoxifen use.
- Thromboembolic events: Risk increases with coadministered chemotherapy. For treatment of
breast cancer, consider risks and benefits in patients with a history of thromboembolic events.
- Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the
potential risk to a fetus and to use effective contraception.
- Effects on the liver: Liver cancer and liver abnormalities, some fatal, have occurred. Perform
periodic liver function testing.
- The most common adverse reactions (≥20% incidence) associated with tamoxifen are hot flashes,
mood disturbances, vaginal discharge, vaginal bleeding, nausea, and fluid retention.
- Anastrozole and letrozole: Should not be used in combination with tamoxifen.
- Warfarin: Do not use in patients taking tamoxifen for DCIS and for reduction in breast cancer
incidence in women at high risk. Closely monitor coagulation indices for increased anticoagulant
effect when used with tamoxifen for metastatic breast cancer or as adjuvant therapy.
- Do not use tamoxifen in lactating women.
- Verify pregnancy status of females prior to initiation of tamoxifen.
- Advise females and males to use effective contraception.
Please see full Prescribing Information for SOLTAMOX.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.